X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Signal Transduction and Targeted Therapy

期刊標題檢索 SIGNAL TRANSDUC 最新評論: I don't understand why there are so many sour grape mentality people w... (2023-08-09)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Signal Transduction and Targeted Therapy]您好,您是該頁面的第 115307 位訪客。

期刊簡介
期刊名稱Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy
LetPub Score
8.6
51 ratings
Rate

Reputation
9.2

Influence
8.0

Speed
9.3

期刊簡稱SIGNAL TRANSDUCT TAR
ISSN2095-9907
E-ISSN2059-3635
h-indexN.A.
CiteScore
CiteScoreSJRSNIPCiteScore Rank
44.508.7375.308
Subject fieldQuartilesRankPercentile
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Genetics
Q12 / 347
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Cancer Research
Q15 / 230

自引率 (2023-2024)1.20%自引率趨勢
掲載範囲
Signal Transduction and Targeted Therapy (ISSN 2059-3635 (online), ISSN 2095-9907 (print), CN 51-1758/R) is a new open access journal, which aims to accomplish timely publication of the latest discoveries and progress in both basic science and clinical research related to signal transduction and targeted therapy. It will include research on major human diseases, including but not limited to: cancer, cardiovascular diseases, autoimmune diseases, and nervous system diseases.
官方網站http://www.nature.com/sigtrans/
在線稿件提交http://mts-sigtrans.nature.com/
開放訪問Yes
出版商Springer Nature
主題領域Biochemistry, Genetics and Molecular Biology
出版國/地區United Kingdom
發行頻率
創刊年2016
每年文章數272每年文章數趨勢
黃金OA百分比99.57%
OA Related Info
APC: Yes( GBP2590; USD3490; EUR2890; )
APC waiver:Check Notes
Other charges: No
Keywords: molecular biology、cell biology、pharmacology、medicinal chemistry、computational chemistry、systems biology
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
BIOCHEMISTRY & MOLECULAR BIOLOGYSCIEQ13/313
CELL BIOLOGYSCIEQ15/205
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2095-9907%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: 5 Weeks
競爭力 *來自作者的數據:
參考鏈接
相關期刊 【Signal Transduction and Targeted Therapy】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    GENOME BIOLOGYH-index: 198

    CiteScore: 21.00
    GENOME BIOLOGYH-index: 207

    CiteScore: 21.00
    GENOME BIOLOGYH-index: 198

    CiteScore: 21.00
    Circulation-Genomic and Precision MedicineH-index: 0

    CiteScore: 9.20
    Frontiers in Genome EditingH-index: 0

    CiteScore: 7.00
    Microbiology SpectrumH-index: 0

    CiteScore: 3.20
    Non-Coding RNAH-index: 0

    CiteScore: 6.70
    Genes and NutritionH-index: 41

    CiteScore: 6.60
    Frontiers in AgingH-index: 0

    CiteScore: 3.00
    Genes and EnvironmentH-index: 0

    CiteScore: 4.00
    學科內最受檢索的期刊 頁面查看次數
    Microbiology Spectrum168265
    Methods in Molecular Biology152193
    GENOME BIOLOGY87067
    GENOME BIOLOGY58598
    Molecular Genetics & Genomic Medicine45603
    Current Medical Science39849
    GENOME BIOLOGY36727
    Mitochondrial DNA Part A26365
    Frontiers in Aging16866
    Circulation-Genomic and Precision Medicine11805
  •  

    Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    下一頁    末頁  (頁
/1)
  [Signal Transduction and Targeted Therapy] 的評論撰寫評論
作者: 科研兴趣小组


領域: 生物学
審稿時間: 2.0 month(s)
結果: 直接被接受


撰寫評論

2023-08-09 15:56:45 評論於
I don't understand why there are so many sour grape mentality people who can't stand to see domestic journals improve. Is mindlessly criticizing interesting? If you have the ability, publish an article there and then speak. Anyway, if our papers are not accepted by top-tier journals or major journals, we will consider submitting them here, but it is also difficult to get accepted. Many papers that were rejected by STTT were accepted by NC, and there are quite a few accepted by Cell Reports. At the very least, this proves that STTT has a higher difficulty level for manuscript submission compared to regular journals.
(0) 讚! | 科研兴趣小组

作者: 科研搬砖民工


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-04-26 10:50:19 評論於
The quality is not that bad, but when will domestic journals stop the farce of impact factor?
(24) 讚! | 科研搬砖民工

作者: prion1


領域: 生物学
審稿時間: 2.0 month(s)
結果: 修改後接受


撰寫評論

2022-07-19 19:29:48 評論於
Submitted in March this year, reviewed for a month, major revisions! Was given a month to make the necessary modifications, then requested an additional month of revision with the editor; revised and resubmitted in June, minor revisions were made during the second review and it was provisionally accepted; in early July, the editorial department made the requested modifications to the images and officially accepted it! The entire process took less than 5 months, showcasing the editors' high efficiency. Wishing everyone success, and may the magazine thrive even further!
(44) 讚! | prion1

作者: cpupierce


領域: 医学
審稿時間: 2.0 month(s)
結果: 直接被接受


撰寫評論

2022-07-04 00:33:45 評論於
Received, the reviewer's comments are very professional, but the handling of the manuscript is slow.
(0) 讚! | cpupierce

作者: 张晓梅


領域: 生物学
審稿時間: 1.0 month(s)
結果: 待定&不明


撰寫評論

2021-03-26 09:32:10 評論於
Although the impact factor is increasing rapidly, most of the impact factors are achieved through letter publications, and it is easier to be accepted by submitting in letter format. However, it is important to remind everyone that a small number of institutions have regulations that letters (excluding Nature's letters) are not considered articles and cannot be used for promotion or awards. Considering this trend, the publication volume of letters in domestic journals is very high, leading to internal competition, and only raising assessment standards. I believe that this trend will continue to spread in the future. Those who want to go far in scientific research should carefully consider submitting letters, including letters from Cell Research, as they may no longer be considered articles in the future.
(75) 讚! | 张晓梅

作者: 布鲁斯


領域: 医学
審稿時間: 1.0 month(s)
結果: 待定&不明


撰寫評論

2021-03-17 19:56:46 評論於
Now there are many manuscripts, not the level of a 5-minute article two years ago. No matter how much is said, go and see the quality of the article for yourself. It's a very good magazine.
(18) 讚! | 布鲁斯

作者: 全式金


領域: 生物
審稿時間: 1.0 month(s)
結果: 直接被接受


撰寫評論

2020-10-29 09:09:30 評論於
How do I say? One article submitted by junior sister apprentice was rejected successively by Oncogene, EBioMedicine, and Cell Death. Later, the supervisor said that this journal had a high impact factor and suggested to submit to it. The impact factor was over 5 in 2018, and it is 14 in 2020. The impact factor has been hyped, and the actual level is estimated to be around 5.

(48) 讚! | 全式金

作者: 全式金


領域: 生物
審稿時間: 1.0 month(s)
結果: 直接被接受


撰寫評論

2020-10-29 09:08:05 評論於
How do I say? One article submitted by junior sister apprentice was rejected successively by Oncogene, EBioMedicine, and Cell Death.

(0) 讚! | 全式金

首頁    上一頁    1    下一頁    末頁  (頁
/1)

開始撰寫 [Signal Transduction and Targeted Therapy] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*